GlassScriptPhysician profile
Ashley R Melugin
NPI 1881094902
$9,444.77
in general payments reported to CMS, 2019-2025
19 companies · $2,696 in 2025
The $2,696 reported for 2025 was more than what 95% of Psychiatric/Mental Health (Nurse Practitioner) providers received nationally (typical 2025 total: $257).
See the full distribution for Psychiatric/Mental Health (Nurse Practitioner)
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $878 · 2022: $1,444 · 2023: $2,235 · 2024: $2,191 · 2025: $2,696.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $7,073 · Education: $48.84.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $7,073.24 |
| Education | $48.84 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Otsuka America Pharmaceutical, INC. | $1,580.09 | 2021-2025 | Rexulti, Abilify Maintena, Abilify Asimtufii |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $1,431.86 | 2021-2025 | Caplyta |
| Teva Pharmaceuticals USA, INC. | $957.38 | 2021-2025 | Uzedy, Austedo Xr, Austedo Xr |
| Vanda Pharmaceuticals INC. | $926.40 | 2021-2025 | Fanapt, Hetlioz |
| Janssen Pharmaceuticals, INC | $874.28 | 2021-2025 | Invega Sustenna, Spravato |
| Neurocrine Biosciences, INC. | $845.89 | 2021-2025 | Ingrezza |
| Alkermes, INC. | $777.82 | 2021-2025 | Aristada, Lybalvi, Aristada Initio |
| Abbvie INC. | $579.73 | 2021-2025 | |
| Lundbeck LLC | $441.85 | 2021-2025 | Rexulti |
| Indivior INC. | $282.69 | 2022-2024 | Perseris |
| Sunovion Pharmaceuticals INC. | $218.77 | 2021-2022 | |
| Axsome Therapeutics, INC. | $159.87 | 2023-2025 | Auvelity |
| Takeda Pharmaceuticals U.S.A., INC. | $109.39 | 2021-2024 | Trintellix |
| Avanir Pharmaceuticals, INC. | $70.86 | 2021 | |
| Idorsia Pharmaceuticals US INC | $55.43 | 2023-2024 | Quviviq |
Show all 19 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| E.R. Squibb & Sons, L.L.C. | $51.16 | 2025 | Cobenfy |
| Eisai INC. | $27.94 | 2021 | |
| Supernus Pharmaceuticals, INC. | $27.41 | 2023-2025 | Qelbree, Qelbree |
| Merck Sharp & Dohme LLC | $25.95 | 2021-2023 | Belsomra |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Ashley Melugin listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.